Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04218513
Other study ID # NJYK-CPEDRV-DDI
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date May 10, 2019
Est. completion date May 31, 2019

Study information

Verified date March 2021
Source Nanjing Yoko Biomedical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An experiment to evaluate the drug-drug interaction of formula edaravone and formula 2-aminoethanesulfonic acid in compound edaravone injection.


Recruitment information / eligibility

Status Completed
Enrollment 24
Est. completion date May 31, 2019
Est. primary completion date May 31, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Age: 18-65 years old (including upper and lower limits); 2. Weight =50 kg, body mass index (BMI) between 18-28 kg / m2 (including upper and lower limits); 3. Understand and sign the informed consent voluntarily, and volunteer to participate in this research. Exclusion Criteria: 1. A history of diseases of the heart, liver, lung, kidney, digestive tract, blood, or neuropsychiatric system judged by the investigator as clinically significant; 2. A comprehensive physical examination, neurological examination, laboratory examination, ECG examination, or cognitive assessment indicates that the subject has an abnormality that the researcher has determined to be clinically significant; 3. Have taken any drug within two weeks before the study administration, and the researcher believes that this situation may affect the evaluation results of this study; 4. There is a history of food or drug allergy or allergies that the researcher judges to be clinically significant; 5. Those with positive results of serological examination (HBsAg, anti-HCV, anti-HIV, TP-Ab); 6. A history of alcohol or drug abuse that the investigator believes may affect the evaluation results of this study within one year before the study administration; 7. Cannot quit smoking or drinking during the study period or the carbon monoxide breath test> 7 ppm during the screening period CO breath test, so if the subject's CO breath is> 7ppm, but the urine cotinine test is negative, it means that the CO breath test result may be false positive, the subject can be enrolled; 8. As a subject who has participated in any drug clinical trial within 3 months before the first administration of the study; 9. Those who donated blood or blood products =400 mL or 2 units within three months of the study; 10. Do not agree to avoid the use of tobacco, alcohol or caffeinated beverages, or vigorous exercise, or other factors that affect drug absorption, distribution, metabolism, excretion, etc. during the 24 hours before and during the test; 11. Pregnant or lactating women, or those who tested positive for serum HCG before the test administration, or those who were unable or unwilling to take researcher-approved contraception during the study according to the researcher's instructions; 12. Subjects with poor compliance or unable to comply with the relevant provisions of the research protocol due to personal reasons, the investigator judges that the subjects are not suitable to participate in this clinical study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Compound Edaravone Injection
30 min intravenous infusion
Edaravone Injection
30 min intravenous infusion
2-Aminoethanesulfonic Acid Injection
30 min intravenous infusion

Locations

Country Name City State
China Beijing Tiantan Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Yoko Biomedical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cmax of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid 24 hours
Primary AUC0-t of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid 24 hours
Primary AUC0-8 of edaravone with and without coIntravenous with 2-Aminoethanesulfonic Acid 24 hours
See also
  Status Clinical Trial Phase
Completed NCT05692570 - A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers Phase 1
Completed NCT04328766 - Pharmacokinetic Interaction Between DWP14012 and DWC202005 in Healthy Volunteers Phase 1
Completed NCT03990129 - Pharmacokinetic Interactions of Metamizole (Dipyrone) in Healthy Subjects Phase 1
Completed NCT03985969 - Study to Investigate the Potential Drug-Drug Interaction Between Elafibranor and Indomethacin Phase 1
Completed NCT03302845 - A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects Phase 1
Completed NCT02887443 - A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate Phase 1
Completed NCT01361217 - The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity N/A
Completed NCT06066060 - A DDI Study of JMKX000623 and Metformin Hydrochloride Phase 1
Completed NCT03723395 - A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib Phase 1
Recruiting NCT05789173 - Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK Early Phase 1
Completed NCT04598542 - Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers Phase 1
Recruiting NCT05044962 - Kuwa Free! - Live Free! N/A
Completed NCT04487145 - Dihydroartemisinin-Piperaquine in the Context of Antiretroviral Therapy Phase 4
Completed NCT05108051 - Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir Phase 1
Active, not recruiting NCT04669678 - Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa Phase 4
Completed NCT01991327 - Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males Phase 1
Completed NCT05492318 - Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity Phase 1
Completed NCT01309854 - Effects of Administration of Fostamatinib on Blood Concentrations of Pioglitazone in Healthy Subjects Phase 1
Recruiting NCT05339672 - Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
Completed NCT05306379 - Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin Phase 1